Research Output per year
Fingerprint Dive into the research topics where Medicine, Hematology Oncology Division is active. These topic labels come from the works of this organization's members. Together they form a unique fingerprint.
Neoplasms
Medicine & Life Sciences
Therapeutics
Medicine & Life Sciences
Breast Neoplasms
Medicine & Life Sciences
Survival
Medicine & Life Sciences
Drug Therapy
Medicine & Life Sciences
Prostatic Neoplasms
Medicine & Life Sciences
Acute Myeloid Leukemia
Medicine & Life Sciences
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Medicine & Life Sciences
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Profiles
Research Output 1956 2019
Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer
Formisano, L., Lu, Y., Servetto, A., Hanker, A. B., Jansen, V. M., Bauer, J. A., Sudhan, D. R., Guerrero-Zotano, A. L., Croessmann, S., Guo, Y., Ericsson, P. G., Lee, K. M., Nixon, M. J., Schwarz, L. J., Sanders, M. E., Dugger, T. C., Cruz, M. R., Behdad, A., Cristofanilli, M., Bardia, A. & 11 others, , Dec 1 2019, In : Nature communications. 10, 1, 1373.Research output: Contribution to journal › Article
Open Access
breast
inhibitors
cancer
Breast Neoplasms
Protein-Tyrosine Kinases
A Case of Metastatic Biliary Tract Cancer Diagnosed Through Identification of an IDH1 Mutation
Kamath, S. D., Lin, X. & Kalyan, A., Feb 1 2019, In : Oncologist. 24, 2, p. 151-156 6 p.Research output: Contribution to journal › Article
Biliary Tract Neoplasms
Mutation
Adenocarcinoma
Neoplasms
Paraffin
1
Citation
(Scopus)
Activation of MAPK Signaling by CXCR7 leads to enzalutamide resistance in prostate cancer
Li, S., Fong, K. W., Gritsina, G., Zhang, A., Zhao, C., Kim, J., Sharp, A., Yuan, W., Aversa, C., Yang, X. J., Nelson, P. S., Feng, F. Y., Chinnaiyan, A. M., De Bono, J. S., Morrissey, C., Rettig, M. B. & Yu, J., Jan 1 2019, In : Cancer Research. 79, 10, p. 2580-2592 13 p.Research output: Contribution to journal › Article
Prostatic Neoplasms
Castration
Androgen Receptor Antagonists
MDV 3100
Androgen Antagonists
Grants 1996 2027
Prot #18157/NU COH19H01: A Phase 2 Front-Line PET/CT-2 Response-Adapted Brentuximab Vedotin and Nivolumab Incorporated and Radiation-Free Management of Early Stage Classical Hodgkin Lymphoma (cHL)
City of Hope National Medical Center, Bristol-Myers Squibb Company
8/12/19 → 8/12/22
Project: Research project
Prot #D933SC00001: A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line Durvalumab in Combination with Standard of Care Chemotherapy and Durvalumab in Combination with Tremelimumab and Standard of Care Chemotherapy Ver
AstraZeneca Pharmaceuticals LP
7/22/19 → 7/22/22
Project: Research project
Prot #G1T48-01: A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Ascending Doses of G1T48 in Women with Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
DrugDev Inc., G1 Therapeutics, Inc.
7/16/19 → 7/16/22
Project: Research project